HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Shipp, M. A. Search for Related Content PubMed PubMed Citation Articles by Shipp, M. A. Social Bookmarking                   What's this?

Molecular Signatures Define New Rational Treatment Targets in Large B-Cell Lymphomas

Correspondence: Margaret Shipp, MD, Dana-Farber Cancer Institute, 44 Binney St., Rm. M513, Boston, MA 02115-6084; phone (617) 632-3874; fax (617) 632-4734; margaret_shipp{at}dfci.harvard.edu

Abstract

Diffuse large B-cell lymphomas (DLBCLs), the most common lymphoid malignancies, are clinically and genetically heterogeneous disorders. Although DLBCL is a chemo-responsive tumor, many patients will not be cured with conventional empiric treatment regimens. Gene expression profiles, analyses of specific genetic abnormalities and functional assays have been used to develop comprehensive molecular signatures of tumors that share similar features and rely upon common survival pathways. These studies are leading to the identification of subtype-specific rational therapeutic targets and associated inhibitors for clinical investigation.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?